Legal and Atypical Drugs of Abuse

1. Introduction and Historical Context

Substance abuse has historically centered on a relatively small number of well-characterized drugs: opioids, stimulants (cocaine, methamphetamine), alcohol, benzodiazepines, cannabis, and hallucinogens (LSD, psilocybin). These drugs have long histories, clear pharmacology, established drug screens, and—critically—legal and regulatory frameworks that clinicians understand. However, over the past two decades, the landscape of drug abuse has fragmented. Internet commerce has democratized pharmaceutical distribution; chemistry has enabled the synthesis of designer drugs; and regulatory frameworks—both domestic and international—have struggled to keep pace with constant drug reformulation.

The Shifting Line Between Legal and Illegal

The boundary between "legal" and "illegal" drugs is increasingly blurred. Kratom (a botanical product) is legal federally in the US but banned in some states. Psilocybin is Schedule I federally but has been decriminalized in Oregon and Colorado, and the FDA has granted "breakthrough therapy" designation for depression treatment. PCP was once a legitimate anesthetic before being withdrawn from human use. Synthetic cannabinoids were originally legal "research chemicals" sold as "K2" or "Spice." The regulatory strategy of governments has been reactive, not proactive: drugs are synthesized, marketed, abused, and only then banned—at which point chemists have already designed analogs to circumvent the bans.

Designer Drugs and the Analogue Act

In 1986, the US Congress passed the Controlled Substance Analogue Enforcement Act (the "Analogue Act"), which criminalizes any chemical "substantially similar" in structure or pharmacology to a Schedule I drug. The intent was to prevent designers from creating legal loopholes. In practice, it has failed spectacularly. Synthetic cathinones (bath salts) emerged circa 2010, marketed as "bath salts" or "plant food" to circumvent the law. When mephedrone and MDPV were scheduled (2012), chemists synthesized alpha-PVP ("flakka"), methylone, and dozens of others. Synthetic cannabinoids followed the same pattern: JWH compounds were banned, replaced by AB-FUBINACA and dozens of other full CB1 agonists. The Analogue Act's weakness is that "substantially similar" is difficult to prove in court; chemists work at the margins of molecular similarity, and prosecutors lack the resources and expertise to prosecute every variant.

How the Internet Changed Drug Availability

Pre-internet, drug distribution relied on street networks with inherent constraints: supplier networks were local, personal relationships created accountability (of a sort), and word-of-mouth spread information slowly. The internet has eliminated these barriers. Kratom is purchased online and delivered to the door. Synthetic cannabinoids are marketed as "herbal incense" on clearnet and darknet vendors. Psilocybin spores (which contain no active alkaloids and are not scheduled) are sold legally online. LSD sold through Tor markets has purity and dosing information provided by vendors competing for reputation. This has created a bifurcated market: legitimate pharmaceutical distribution (regulated by FDA, with quality control) and internet-mediated black markets (unregulated, no quality control, variable potency, high contamination risk). The latter is where most emerging drugs of abuse circulate.

2. Kratom (Mitragyna speciosa)

Botanical Origin and Alkaloid Chemistry

Kratom is a tropical tree native to Southeast Asia (Thailand, Malaysia, Indonesia, Papua New Guinea). Leaves contain over 40 alkaloids, with mitragynine (~5-7% by weight in dried leaf) and 7-hydroxymitragynine (~0.01-0.04%) as the primary psychoactive compounds. Dried kratom leaves are consumed as a powder, tea, or capsule. Users typically consume 5-15 grams per dose. The pharmacology is dose-dependent: low doses produce stimulant-like effects; higher doses produce sedation and analgesia.

Mechanism of Action

Mitragynine is a partial mu-opioid receptor agonist (and weak kappa/delta agonist), along with activity at monoamine receptors. 7-hydroxymitragynine is a more potent mu-opioid agonist. At low doses (3-5g), kratom users report enhanced focus, energy, and mild euphoria—mediated by adrenergic activity. At higher doses (10-15g+), opioid-mediated analgesia, sedation, and euphoria predominate. The partial agonist nature of mitragynine (compared to full agonists like morphine) means pharmacologically it occupies a space between endogenous opioids and pharmaceutical opioids, with weaker intrinsic activity but still capable of producing physical dependence.

Legal Status

Kratom is legal federally in the United States and in most states. However, it is banned in six states (Alabama, Arkansas, Indiana, Tennessee, Vermont, Wisconsin) and the District of Columbia. Thailand (where it originates) banned kratom in 1943 and only partially decriminalized it in 2018. The FDA has not approved kratom for any medical indication and has issued warnings about adulteration, contamination with opioids, and adverse effects.

Abuse Potential and Physical Dependence

Kratom has significant abuse potential and can produce opioid-like physical dependence and withdrawal. Users developing chronic daily use (often self-treating chronic pain or opioid use disorder) develop tolerance; abrupt cessation produces withdrawal syndrome resembling opioid withdrawal: dysphoria, anxiety, muscle aches, insomnia, rhinorrhea, and mild autonomic symptoms. Withdrawal typically peaks at 24-48 hours and resolves over 5-10 days—milder than heroin withdrawal but real. Some users self-escalate doses from 5g to 30-50g daily. The pharmacology of the substance and the behavioral pattern (self-treatment for pain/withdrawal avoidance, escalating doses, use despite harm) clearly establish abuse potential. Heavy users report that cessation is difficult, and relapse is common.

Risks and Toxicology

Hepatotoxicity is the most widely documented organ-specific risk: more than 100 cases of liver injury have been reported to FDA MedWatch, with some progressing to acute liver failure and death. The mechanism is unclear—possibly alkaloid direct toxicity, contaminants, or immune-mediated. Seizures have been reported, particularly in users escalating doses or using contaminated preparations. Kidney injury, thromboembolism, and encephalopathy have been documented in case reports. Deaths attributed to kratom almost always involve polysubstance use (kratom + opioids, kratom + benzodiazepines, kratom + alcohol), making causality attribution difficult. However, severe adverse events and deaths occur in users not reporting co-use, suggesting kratom itself carries serious risk at high doses or in vulnerable individuals.

Contamination and Quality Control

Kratom is unregulated; no pharmaceutical quality standards apply. Testing for heavy metals (lead, cadmium, mercury) has revealed high contamination in some batches. Microbial contamination (E. coli, Salmonella) has been documented. Some vendors have been found to adulterate kratom with pharmaceutical opioids (tramadol, codeine) or benzodiazepines, creating false efficacy and unsuspecting users developing dependence on undisclosed co-drugs.

Clinical Presentation

Acute kratom intoxication resembles mild opioid intoxication: miosis (pinpoint pupils), sedation, analgesia, mood elevation, and constipation. Users may present to the ED with respiratory depression, though cases of severe respiratory depression are rare (unlike heroin or fentanyl overdose). Chronic kratom use can cause nausea, constipation, weight loss, and pallor. Withdrawal presents as dysphoria, anxiety, insomnia, body aches, and rhinorrhea—again resembling opioid withdrawal but usually milder. Liver injury presents as jaundice, pruritus, right upper quadrant abdominal pain, and elevated transaminases. Encephalopathy (in advanced liver disease) presents as confusion, asterixis, and impaired consciousness.

Use in Self-Treatment of Opioid Withdrawal

Kratom is widely promoted on internet forums as a treatment for opioid withdrawal. Some evidence suggests low-dose kratom can reduce withdrawal symptoms acutely. However, this creates a substitution pattern: users switch from prescription opioids or heroin to kratom, develop kratom dependence, and face a new withdrawal syndrome. Clinically, managing kratom-dependent patients requires detoxification (tapering or abrupt cessation with symptomatic treatment), psychosocial support, and monitoring for psychiatric complications (depression, anxiety).

3. Bath Salts (Synthetic Cathinones)

What Are Bath Salts?

Synthetic cathinones are designer drugs chemically derived from cathinone—a beta-keto amphetamine found in the khat plant (Catha edulis), which has been used as a mild stimulant in East Africa for centuries. Synthetic variants were created in laboratories beginning in the early 2000s. The original compound, mephedrone, was synthesized in 1929 but remained obscure until ~2008 when it was marketed online as "bath salts" or "plant food" under names like "Meow Meow." Other variants quickly emerged: methylone (related to MDMA), MDPV (methylenedioxypyrovalerone), and alpha-PVP (α-pyrrolidinopentiophenone, "flakka"). These compounds are typically white or off-white powders, snorted, ingested, or injected IV.

Mechanism of Action

Synthetic cathinones are monoamine reuptake inhibitors and releasers. Unlike cocaine and amphetamine (which are weak to moderate serotonin reuptake inhibitors), synthetic cathinones are potent 5-HT releasers, producing intense serotonergic activity alongside dopaminergic and noradrenergic effects. MDPV and mephedrone are exceptionally potent: 5-10mg IV can produce profound intoxication. This pharmacology explains the high addictiveness and unique toxidromes: the intense dopaminergic rush drives compulsive redosing, while extreme serotonergic activity creates psychosis, agitation, and autonomic instability.

History and Emergence

Synthetic cathinones emerged as legal highs circa 2010. Sold as "bath salts," "plant food," or "jewelry cleaner," they exploited regulatory gaps. When mephedrone was scheduled in the UK (2010) and the US (2011), chemists reformulated. The Analogue Act should have covered these as cathinone analogues, but legal proceedings were slow, and new compounds were constantly synthesized. By 2012, MDPV, methylone, and mephedrone were scheduled federally. However, alpha-PVP and numerous others remained legal. Alpha-PVP emerged as particularly popular ("flakka") around 2014-2015, causing thousands of ED visits and psychiatric crisis episodes. Even as compounds are scheduled, new analogs appear within months.

Legal Status

Mephedrone, methylone, and MDPV are DEA Schedule I. Alpha-PVP was temporarily scheduled in 2014, then more permanently scheduled in 2015. However, a steady stream of chemical variants (eutylone, N-ethylpentylone, etc.) remain or enter gray zones of legality. Vendors modify the chemical structure just enough to claim non-compliance with the Analogue Act. This regulatory cat-and-mouse game is ongoing.

Abuse Potential and Compulsive Use

Synthetic cathinones have extremely high abuse potential and produce intense psychological dependence. Unlike heroin (which gradually depresses the user into a nod), synthetic cathinones produce repeated brief rushes when redosed. Users report compulsive patterns: a user obtains 1 gram, intends to use it sparingly, but within hours has consumed all of it by repeated IV or nasal dosing. The drugs are described as more-ish (mephedrone is literally called "meow meow" because the high is so reinforcing). Addiction develops rapidly, often within days to weeks of use. Psychological dependence is severe: users in withdrawal report crushing anhedonia, suicidal ideation, and intense cravings.

Acute Toxicity and Emergency Presentation

Synthetic cathinones produce a constellation of acute toxidromes:

• Psychosis: Visual, auditory, and tactile hallucinations; paranoia; delusional thoughts. Patients may present to the ED convinced they are being hunted, their house is bugged, or insects are crawling under their skin (formication). This is indistinguishable from acute schizophrenia or methamphetamine psychosis.
• Excited Delirium: Agitation, violent behavior, superhuman strength, imperviousness to pain, combativeness with police or ED staff. This is a medical emergency with high mortality.
• Hyperthermia: Core body temperatures exceeding 40-41°C are common in excited delirium. This is life-threatening and causes organ damage.
• Rhabdomyolysis: Extreme muscle exertion from agitation and loss of pain sensation causes muscle breakdown; myoglobin overwhelms renal function, causing acute kidney injury (AKI). Creatinine kinase (CK) can exceed 10,000-100,000 U/L.
• Cardiovascular Collapse: Tachycardia to 140-160 bpm, hypertension (BP 160-200+/110+), arrhythmias, myocardial infarction, and sudden cardiac death have been documented. Patients in their 20s have suffered MIs.
• Seizures: Status epilepticus can occur.
• Acute Coronary Syndrome: Chest pain, ST elevation, troponin elevation.

Emergency Management

Management is largely supportive: cooling (cold IV fluids, ice packs, evaporative cooling), aggressive sedation (benzodiazepines, sometimes requiring propofol or intubation), correction of electrolytes (particularly potassium and magnesium in the context of rhabdomyolysis), aggressive fluid resuscitation for AKI prevention, continuous cardiac monitoring, and ICU admission for severe cases. Antipsychotics (haloperidol, risperidone) can be used for psychosis, but benzodiazepines are first-line for acute agitation. Restraint should be minimized (increases hyperthermia and rhabdomyolysis risk). Mortality in excited delirium with severe hyperthermia and rhabdomyolysis approaches 10-20%, even with aggressive treatment.

4. Spice/K2 (Synthetic Cannabinoids)

What Are Synthetic Cannabinoids?

Synthetic cannabinoids are laboratory-synthesized compounds designed to activate cannabinoid receptors (CB1 and CB2). The most commonly encountered are JWH compounds (JWH-018, JWH-250, etc., named after John W. Huffman who synthesized them for research purposes), followed by AB-FUBINACA, AB-PINACA, ADB-BUTINACA, and dozens of others. These are typically sprayed onto dried plant material and smoked; they are also available in liquid form for vaping. Potency varies wildly: standard cannabis (THC ~10-20%) has predictable effects, while synthetic cannabinoid products are dosed haphazardly—a single joint might contain 20-100mg of JWH-018, compared to ~5-10mg of THC in a standard joint.

Mechanism of Action: Full vs. Partial Agonism

This is the critical distinction: THC is a PARTIAL agonist at CB1 receptors, with intrinsic activity around 0.4-0.7. This partial agonism limits THC's maximal effect. Synthetic cannabinoids like JWH-018 and AB-FUBINACA are FULL agonists at CB1, with intrinsic activity near 1.0. Full agonists produce stronger receptor activation and greater physiological effects than partial agonists at the same receptor occupancy. This explains why synthetic cannabinoids produce far more severe intoxication, psychosis, seizures, and other adverse effects compared to cannabis. Additionally, some synthetic cannabinoids have higher affinity for CB1 than THC, further amplifying effects.

Legal Status and Constant Reformulation

JWH-018 and other early compounds were scheduled as Schedule I in 2009-2012. Manufacturers have continuously reformulated. AB-FUBINACA and AB-PINACA emerged in 2014-2015. The same regulatory cycle repeats: a compound is synthesized, marketed, causes hospitalizations, is banned, and is replaced by a new variant. The Analogue Act is theoretically applicable, but enforcement is slow and manufacturers stay ahead. Most synthetic cannabinoids sold today are technically not scheduled compounds (though this changes monthly), operating in legal gray zones.

Abuse Potential

Synthetic cannabinoids have moderate to high abuse potential. Unlike cannabis, where psychological dependence develops gradually over months to years of daily use, synthetic cannabinoids produce dependence more rapidly. Heavy users (daily smoking) develop tolerance and withdrawal: dysphoria, anxiety, irritability, sleep disturbance, and decreased appetite when ceasing use. The withdrawal is milder than opioid or alcohol withdrawal but real. Psychological dependence is substantial—many chronic users report difficulty stopping despite desired consequences (job loss, relationship damage, medical complications).

Acute Toxicity and Organ-Specific Risks

• Seizures: One of the most distinguishing features of synthetic cannabinoid intoxication. Seizures can be single or repeated (status epilepticus). Some users present with first-time seizure activity. The mechanism is likely CB1 hyperactivation, imbalance of excitatory/inhibitory neurotransmission.
• Acute Kidney Injury (AKI): Dozens of cases of AKI have been reported, progressing to renal failure requiring dialysis. The mechanism is unclear—possibly direct toxicity, rhabdomyolysis, or immune-mediated. Some reports suggest a hepatotoxic or cardiotoxic event triggers secondary renal dysfunction.
• Coagulopathy and Bleeding: Some batches of synthetic cannabinoids have been contaminated with brodifacoum (a super-warfarin rodenticide used in pesticides). Patients present with severe coagulopathy, elevated INR, bleeding from gums, hematuria, hemoptysis, and intracranial hemorrhage. This is an iatrogenic/contamination issue, not inherent to the drug.
• Myocardial Infarction: Young, healthy patients have suffered acute MI associated with synthetic cannabinoid use. Mechanism is likely sympathomimetic (tachycardia, hypertension) with demand ischemia, direct coronary vasospasm, or thrombosis.
• Psychosis: Visual and auditory hallucinations, paranoia, delusional thinking, disorganized speech. Often lasts hours to days after cessation.
• Severe Agitation and Violence: Unlike cannabis, which typically causes relaxation, synthetic cannabinoids produce agitation, combativeness, and unpredictable violence.

Clinical Presentation and Emergency Management

An acute presentation might include agitation, visual hallucinations, paranoia, tachycardia, hypertension, diaphoresis, tremor, and—critically—seizure activity. Management includes IV access, seizure precautions/benzodiazepine administration (lorazepam 2-4mg IV for acute seizures or lorazepam drip for recurrent seizures), cardiac monitoring, ECG, chest X-ray, troponin, basic metabolic panel (BUN, creatinine for AKI), coagulation studies (PT/INR, PTT, CBC), and urinalysis. If seizure is first-time or status epilepticus develops, ICU admission is warranted. If AKI is present, fluid resuscitation and nephrology consultation are indicated. If coagulopathy is present, vitamin K and fresh frozen plasma may be necessary.

Screening and Detectability

Standard urine drug screens do NOT detect synthetic cannabinoids. Detection requires specific testing (immunoassay or mass spectrometry); most labs do not routinely perform this. A patient presenting with seizure, AKI, MI, or psychosis attributed to "spice" or "K2" use may be admitted without a documented positive screen, making diagnosis clinical and based on history.

5. Psilocybin (Magic Mushrooms)

Botanical Source and Mechanism

Psilocybin is a naturally occurring indole alkaloid found in over 200 species of mushrooms in the genus Psilocybe, as well as some Copelandia and Panaeolus species. It is found worldwide in soil and on dung. Psilocybin itself is inactive; it is a prodrug metabolized by alkaline phosphatase in the gut to psilocin, the active compound. Psilocin is a 5-HT2A serotonergic agonist, with additional activity at 5-HT1A, 5-HT1D, 5-HT6, and 5-HT7 receptors, and dopamine receptors. Typical doses range from 5-30 mg dried mushroom material (0.5-3g fresh). Effects begin at 30-60 minutes, peak at 2-3 hours, and typically resolve over 4-6 hours, though visual disturbances can persist longer.

Pharmacology and Effects

Psilocin produces classic psychedelic effects: visual alterations (geometric patterns, color distortions, visual snow, morphing), emotional changes (euphoria, mystical feelings, profound introspection, or anxiety/terror in difficult experiences), altered time perception, sense of unity with surroundings, and ego dissolution (a sense that the self/ego boundaries dissolve). Users often describe experiences as profoundly meaningful or existential. The serotonergic 5-HT2A agonism is the primary mechanism; dopaminergic activity contributes to reward and reinforcement. Most research suggests 5-HT2A is both necessary and sufficient for the psychological effects.

History and Legal Status

Psilocybin mushrooms have been used in religious and shamanic ceremonies by Mesoamerican cultures for millennia. Following Hofmann's identification of psilocybin (1958) and Leary's psychological research (1960s), psilocybin became a symbol of 1960s counterculture. The US placed psilocybin on Schedule I in 1970. Over the past decade, legal status has shifted dramatically: Oregon (2020) decriminalized psilocybin mushrooms and legalized psilocybin-assisted therapy (with implementation in 2023). Colorado decriminalized in 2022. Canada has granted exemptions for end-of-life care and PTSD treatment. The FDA designated psilocybin-assisted therapy as "breakthrough therapy" for treatment-resistant depression (2018) and for PTSD (2023), accelerating clinical research.

Abuse Potential

Psilocybin has very low abuse potential. Physical dependence does not develop; repeated use produces rapid tolerance (typically within 3-5 days of daily use, resolving within a week of abstinence), which discourages compulsive daily dosing. Psychological dependence is rare—users may desire to use psilocybin again, but the subjective experience is not euphoria-driven (unlike opioids or cocaine) and the intense nature of the experience often leads to spacing of use (monthly, yearly) rather than daily escalation. No withdrawal syndrome develops with cessation. Addiction is extremely uncommon.

Risks and Adverse Effects

• Bad Trips: A minority of users (~10-30%) experience severe anxiety, panic, paranoia, or terror during a psilocybin session. This is self-limited (duration of the drug effect, 4-6 hours) but psychologically distressing. Reassurance, a calm environment, and possibly benzodiazepines (lorazepam 1-2mg PO/IM) are helpful.
• Hallucinogen Persisting Perception Disorder (HPPD): A rare but documented condition where visual disturbances (geometric patterns, visual snow, flashes) persist for weeks to months after the drug effect has worn off. Most cases resolve spontaneously; treatment is largely reassurance and anxiolytics if distress is significant.
• Precipitation of Psychosis: In individuals with latent or predisposed psychosis (family history of schizophrenia, personal history of psychotic episodes), psilocybin can precipitate acute psychosis. This is not an overdose effect; it is a drug-gene or drug-predisposition interaction. Psychosis may persist beyond the acute drug effect (hours to days) and require antipsychotic treatment.
• Serotonin Syndrome: Theoretical risk if combined with SSRIs, MAOIs, or other serotonergic agents. Documented cases are rare, but the combination should be avoided or undertaken carefully with dose reduction.

Clinical Research and Therapeutic Use

Over 100 clinical trials are currently underway examining psilocybin-assisted therapy for depression, anxiety, addiction (tobacco/alcohol), PTSD, and end-of-life existential anxiety. Phase 2 trials have shown efficacy for treatment-resistant depression (approximately 50-70% response rate) in doses of 10-30mg (therapeutic dose is much lower than recreational "trip" doses). The therapeutic model involves single or repeated doses of psilocybin in a controlled setting with psychological support before and after dosing. Outcomes appear durable: patients show sustained improvement 6-12 months post-therapy without requiring repeated dosing.

6. Peyote (Mescaline)

Botanical Source and Pharmacology

Peyote is a small spineless cactus (Lophophora williamsii) native to the Chihuahuan Desert (Mexico and southern Texas). The plant contains mescaline (3,4,5-trimethoxyphenethylamine), the primary psychoactive alkaloid (0.4-0.7% by dry weight in buttons/crowns). Mescaline is a 5-HT2A agonist (like psilocin), producing classic psychedelic effects. Typical doses are 5-10 peyote buttons (or 100-300mg pure mescaline), with effects lasting 8-12 hours. Duration is longer than psilocybin.

Mechanism and Effects

Mescaline produces indistinguishable effects from psilocybin: visual alterations, emotional changes, sense of unity, ego dissolution. The 5-HT2A agonism is the primary mechanism. Mescaline is metabolized by MAO-A, with a peak plasma concentration at 1-2 hours. Some users report the experience as more chaotic or overwhelming than psilocybin; others describe it as more gentle. Subjective variation is high.

Legal Status and Religious Exemption

Mescaline is Schedule I federally in the US. However, the American Indian Religious Freedom Amendment Amendments Act (AIRFA, 1994) and subsequent Religious Land Use and Institutionalized Persons Act (RLUIPA, 2000) provide an exemption: members of the Native American Church (NAC) are legally permitted to use peyote in religious ceremonies. This exemption is remarkable in US drug law—peyote remains Schedule I for the general public but is legal for NAC members. The NAC was founded in the late 1800s and currently has approximately 250,000 members. Peyote use in NAC ceremonies is highly controlled and ritualized; abuse or diversion is minimal.

Abuse Potential and Clinical Considerations

Outside the NAC context, peyote abuse is rare. Like psilocybin, mescaline has low abuse potential, does not produce physical dependence, and carries low addiction risk. Risks are similar to psilocybin: bad trips, HPPD, precipitation of psychosis in vulnerable individuals. Clinical management is identical: reassurance, benzodiazepines for acute anxiety, antipsychotics if psychosis develops.

7. PCP (Phencyclidine)

History and Development

Phencyclidine (1-(1-phenylcyclohexyl)piperidine) was synthesized in 1959 by Parke-Davis chemist Edward Ravitch as a potential intravenous anesthetic. It showed promise (rapid onset, no respiratory depression, analgesia), and was tested in humans in the 1960s under the brand name Sernyl. However, emergence reactions—hallucinations, confusion, disorientation, agitation—were severe and frequent, limiting clinical use. It was withdrawn from human trials and marketed for veterinary use as Sernylan (a dissociative anesthetic for animals). It was never FDA-approved for human medicine and became a scheduled substance. However, clandestine synthesis began in the 1960s, and illicit PCP became a street drug. Peak abuse was in the 1980s-90s in urban areas.

Mechanism of Action

PCP is a non-competitive NMDA receptor antagonist—it blocks the ion channel of the NMDA (N-methyl-D-aspartate) glutamate receptor, preventing calcium influx. This dissociative mechanism explains the anesthetic, analgesic, and amnestic effects. Additionally, PCP is a dopamine D1 and D2 receptor antagonist, and it has activity at sigma-1 and sigma-2 receptors. The NMDA antagonism is the primary mechanism for the dissociative effects (sense of unreality, detachment, anesthesia).

Routes of Administration and Street Forms

PCP is available as a powder ("angel dust"), typically snorted or smoked. It is also dissolved in liquid and sprayed onto cigarettes ("wet," "fry," "amp") or cannabis ("sherm," "illy"). Typical doses are 5-20mg smoked/insufflated. Effects begin within minutes; peak at 30-60 minutes; and can last 4-6 hours (though residual effects persist for 24-48 hours). IV use is rare on current streets but produces intense rapid onset.

Acute Intoxication and Toxidrome

PCP intoxication produces a distinctive constellation of effects:

• Dissociation and Anesthesia: The user feels separated from their body, experiences loss of pain sensation (anesthesia), and may not recognize injuries. A user might be unaware of broken bones or severe lacerations.
• Nystagmus: Characteristic vertical and horizontal nystagmus (rapid involuntary eye movements) is a hallmark sign of PCP intoxication. Nystagmus is not seen with most other drugs and is highly specific for PCP (or other NMDA antagonists like ketamine/dextromethorphan).
• Ataxia and Dysarthria: Uncoordinated movements, slurred speech, impaired balance.
• Hypertension and Tachycardia: Sympathomimetic effects, often marked (BP 150+/100+, HR 120+).
• Psychosis: Hallucinations, paranoia, delusional thoughts. Particularly prominent at higher doses.
• Agitation and Unpredictable Behavior: Some users are sedated; others are extremely agitated, combative, and violent. Violence associated with PCP is legendary in emergency medicine and law enforcement. Users become combative, require multiple officers/security personnel to restrain, and have reported superhuman strength. The anesthesia from NMDA antagonism means the user feels no pain from restraint or self-injury.
• Seizures: Can occur with higher doses.

Serious Risks

• Rhabdomyolysis: Extreme agitation and muscle exertion, combined with inability to feel pain (leading to further self-injury), cause muscle breakdown. CK can exceed 10,000 U/L. Secondary AKI is common.
• Hyperthermia: Uncontrolled muscle activity and autonomic instability can cause dangerous elevations in body temperature.
• Violent Behavior and Injury to Self and Others: PCP users are more likely to assault healthcare providers, police, or bystanders than users of other drugs. Some of the most graphic cases of violence in emergency medicine involve PCP intoxication.
• Respiratory Depression: At very high doses or with co-ingestion of opioids/sedatives, respiratory depression can occur. Death from respiratory depression is possible but less common than with opioids.

Clinical Presentation and Emergency Management

A patient with PCP intoxication presents with nystagmus (vertical and horizontal), agitation, possible psychosis, marked hypertension and tachycardia, disorganized behavior, and potentially violence. Key diagnostic clues are nystagmus and the constellation of dissociation + agitation + anesthesia. Management requires: (1) Safety first—potential for violence is high; security presence and de-escalation are critical; (2) IV access if possible, though restraint may be necessary; (3) Continuous monitoring (cardiac monitor, BP, oxygen saturation); (4) Benzodiazepines (lorazepam 2-4mg IV) for acute agitation; (5) Cooling measures if hyperthermic; (6) CK, renal function, electrolytes, urinalysis if rhabdomyolysis is suspected; (7) ICU admission for severe cases; (8) Psychiatric evaluation once acutely medically stable—psychotic symptoms from PCP can persist for days.

8. LSD (Lysergic Acid Diethylamide)

History and Synthesis

LSD was first synthesized in 1938 by Albert Hofmann, a Swiss chemist at Sandoz Laboratories, in an attempt to create a respiratory and circulatory stimulant. Its psychoactive effects were discovered accidentally in 1943 when Hofmann ingested a small amount and experienced profound visual hallucinations. He subsequently conducted the first formal self-experiment ("bicycle day," April 16, 1943). Sandoz synthesized and distributed LSD for research purposes in the 1950s-60s, particularly in psychiatric research and CIA's MK-Ultra program (covert LSD experiments without informed consent). During the 1960s counterculture, LSD became emblematic of psychedelic exploration, associated with figures like Timothy Leary and the Grateful Dead. The US placed LSD on Schedule I in 1970. Today, LSD remains a Schedule I drug federally, though some jurisdictions have decriminalized it or are exploring it for therapeutic use (similar to psilocybin).

Mechanism and Pharmacology

LSD is a semi-synthetic compound derived from lysergic acid, an alkaloid found in ergot fungus (Claviceps purpurea) that grows on rye and other grains. LSD is a 5-HT2A agonist (like psilocybin and mescaline), with additional activity at 5-HT1A, 5-HT7, dopamine D1/D2 receptors, and trace amine receptors. The 5-HT2A agonism is responsible for the visual hallucinations and altered perception. Potency is exceptional: an active dose is 50-200 μg (micrograms)—50,000-100,000 times more potent than psilocybin by weight. LSD is typically dosed on blotter paper, microdots, or in liquid form (often cited as "40x" or other multiples indicating concentration). A standard dose is 1-2 tabs (100-200μg). Onset is 30-60 minutes; peak is 2-4 hours; duration is 8-12 hours (can feel longer due to altered time perception).

Pharmacology and Effects

LSD produces classic psychedelic effects: visual hallucinations (geometric patterns, color distortions, synesthesia where senses cross—"seeing sounds," "tasting colors"), emotional shifts (euphoria, anxiety, profound introspection), altered time perception, ego dissolution, and sense of mystical or cosmic significance. Most users describe the experience as profound and meaningful. Unlike some other drugs, LSD does not typically produce appetite changes, significant autonomic instability, or physical discomfort during the experience (though nausea and headache can occur). The experience is often described as clearer or more lucid than psilocybin—the mind feels sharp and insightful, not foggy.

Abuse Potential and Dependence

LSD has no physical dependence potential. Repeated use does not produce tolerance—each use produces full effects (unlike alcohol or benzodiazepines where repeated dosing produces tolerance). Addiction does not develop; there is no craving or compulsive use pattern. Users may desire to experience LSD again, but the intensity of the experience often leads to infrequent use (monthly, yearly) rather than frequent escalation. Psychological dependence is essentially absent—users are not driven by dysphoric withdrawal or anhedonia into compulsive use.

Risks and Adverse Effects

• Bad Trips: Like psilocybin, a minority of LSD users experience severe anxiety, paranoia, or terror. Most are self-limited to the duration of the drug effect (8-12 hours), though psychological distress can persist beyond acute intoxication. Management is reassurance and benzodiazepines if severe.
• HPPD: Hallucinogen persisting perception disorder—persistent visual disturbances after acute effects wear off. Rare but documented; most cases resolve spontaneously.
• Precipitation of Psychosis: In individuals predisposed to psychosis (family history, prior episodes), LSD can trigger acute psychosis. Psychosis may persist beyond the acute drug effect and require antipsychotic treatment.
• Serotonin Syndrome: Theoretical risk if combined with SSRIs or other serotonergic agents, though documented cases in humans are rare. The combination should be avoided or done cautiously with dose reduction.
• Flashbacks: Some users report spontaneous recurrence of visual hallucinations hours to days after the acute drug effect has worn off. The mechanism is unclear; it may be a form of HPPD or a conditioned response to environmental triggers. Most are benign and self-resolve.

Current Research and Therapeutic Potential

Like psilocybin, LSD is being studied for therapeutic potential in depression, anxiety, PTSD, and addiction. Early trials have shown promise. The potential advantage of LSD over psilocybin is the longer duration (8-12 hours vs 4-6 hours), which some researchers believe allows more time for psychological integration. However, trials are limited by legal constraints (Schedule I status makes obtaining pure research-grade LSD difficult). Some research is occurring in Europe (Switzerland, Germany) where regulatory frameworks are more permissive.

9. Summary and Comparison Table

The following table provides a comprehensive overview of the substances discussed, highlighting key clinical features for rapid reference:

Key Clinical Takeaways:

• Legal status does not correlate with safety or abuse potential. Kratom is legal but carries significant dependence risk. Psilocybin is Schedule I but has minimal abuse potential and emerging therapeutic evidence.
• Standard drug screens do not detect most of these substances (kratom, synthetic cannabinoids, synthetic cathinones, psilocybin, LSD). Diagnosis relies on clinical history and examination for specific toxidromes.
• Excitement delirium, rhabdomyolysis, and hyperthermia are medical emergencies associated with synthetic cathinones and PCP. Aggressive cooling, sedation, and monitoring are critical.
• Dissociation (PCP) and anesthesia to pain are high-risk features promoting violent behavior and self-injury. Restraint should be minimized and approached cautiously.
• Psychosis precipitation in individuals with family history of schizophrenia or prior psychotic episodes is a real risk for hallucinogens (psilocybin, mescaline, LSD). Personal and family history is critical in risk assessment.
• Synthetic cannabinoids and cathinones constantly reformulate as new compounds are scheduled, making "schedules" perpetually out of date. Clinical recognition is based on toxidromes, not substance name.
• Contamination (synthetic cannabinoids with brodifacoum, bath salts with fentanyl, kratom with benzodiazepines) is a significant and often unrecognized risk in illicit markets.

Scope of the Problem

The emergence of legal and atypical drugs of abuse represents a significant public health challenge. Emergency departments report increasing presentations of synthetic cathinone and synthetic cannabinoid intoxication, with life-threatening toxidromes. Poison control centers field hundreds of calls annually related to kratom overdose and withdrawal. Psychiatric services encounter individuals with psilocybin or LSD-related psychosis or HPPD. The regulatory framework has not kept pace with synthesis; scheduling takes years, and analogs appear within months. Public health messaging around these drugs is often absent or confusing—"legal" does not mean safe, and "natural" (kratom, psilocybin) does not mean harmless. Clinicians must be prepared to recognize toxidromes, provide emergent management, and counsel patients on risks with accuracy and without stigma.